Dutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum.
Swiss Versantis AG has raised money in order to advance its liver detoxifying candidate VS-01 from ongoing Phase Ia trials to initial Phase IIa efficacy proof.
Danish Lundbeck AS is has secured a stake in the migraine market by paying US$1.95bn (€1.76bn) to acquire Alder BioPharmaceuticals Inc.
Prague-based PPF Group has acquired a 19.2% stake in Autolus Therapeutics plc, a developer of T cell cancer therapies.
The Board of Directors of Menarini Group has appointed Mrs. Elcin Barker Ergun as CEO.
German and US researchers have found a biomarker that identifies tumours responding to CTLA-4 checkpoint blockers.
French biotech Inotrem SA raised €39m to finance Phase IIb efficacy testing of its TREM1 blocker nangibotide (Motrem) in patients with septic shock.
Paris-based Ermium Therapeutics has completed a Series A financing to develop breakthrough auto-immune therapeutics.
Leiden-based Pharvaris BV received a cash injection that will be used to push PHA121, the very first orally administered hereditary angioedema (HAE) drug.
London and Boston-based 4BIO Ventures has raised US$50m to target early-stage developers of advanced therapies by means of its new 4Bio Ventures II fund.